Xenogen is Next Piece in Caliper s Discovery Continuum ; High-Content Play is on Horizon | GenomeWeb

Caliper Life Sciences this week announced that it will acquire small-animal imaging firm Xenogen in a bid to broaden its palette of drug-discovery tools and hopefully generate what it estimates to be 10 percent to 15 percent top-line growth for the combined company.

The $80 million deal provides Caliper its first taste of an imaging platform for drug discovery, and falls in line with the company's strategy to be a complete pipeline drug-discovery tools and service vendor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.